While the number of ALK mutation‐positive NB patients on primary diagnosis is in the range of 8–10%, this figure increases substantially in the relapsed patient population (Martinsson et al, 2011; Schleiermacher et al, 2014; Eleveld et al, 2015). The gene discussed is ALK; the disease is neuroblastoma.